Pharmaceutical Pricing & Reimbursement Information ÖBIG Warsaw 29 October Price Volume Agreements PPRI Project Christine Leopold Gesundheit Österreich GmbH PPRI Conference Warsaw, 29 October 2007

Pharmaceutical Pricing & Reimbursement Information ÖBIG Warsaw 29 October  Pricing policies  Price control (statutory pricing, price negotiation, public procurement)  Free pricing  Pricing procedures  External price referencing  Internal price referencing  Cost-plus  Others (e.g. indirect price control) Terminology regarding pricing

Pharmaceutical Pricing & Reimbursement Information ÖBIG Warsaw 29 October  For all pharmaceuticals (BE, BG, CY, CZ, EL, LU; TR)  For POM (NL, PT; NO)  For reimbursable pharmaceuticals  Most common pricing policy  No price control  DK - however linkage to reimbursement  MT Pricing policies Price control (at price setting level)

Pharmaceutical Pricing & Reimbursement Information ÖBIG Warsaw 29 October  Statutory pricing  e.g. BE, BG, CY, CZ, EL, ES, LT, LU, PT, SE; NO, TR  Negotiations (FR, IT)  Mixture  Statutory pricing after negotiations (EE, LV, PL)  Price Volume Agreements (e.g. EE)  Public procurement in the hospital sector Pricing policies Way of price control

Pharmaceutical Pricing & Reimbursement Information ÖBIG Warsaw 29 October  Claw-back  A system allowing third party payers to recoup (part of the) discounts/rebates granted in a reimbursement system between various stakeholders, e.g. wholesalers and pharmacists  Examples are NL and UK  Pay-back  A financial mechanism that requires manufacturers to refund a part of their revenue to a payer (i.g. social health insurance / national health service) if sales exceed a previously determined or agreed target-budget.  Example FR Other ways of control costs